FibroBiologics Hosts Webinar on Cell Therapy Platform Updates
News related to:FibroBiologics, Inc · 2 min read
ORLANDO, Fla., November 12, 2026 /CourierPR/ -- FibroBiologics, a clinical-stage biotechnology company based in Houston, is set to host a live investor webinar on Thursday, November 19, 2026, at 4:15 p.m. Eastern Time. The event, organized by RedChip Companies, aims to provide an update on the company's progress in developing an off-the-shelf therapeutic platform based on fibroblast cells. This platform is designed to harness the regenerative and immune-modulating properties of fibroblasts for various high-value indications.
During the webinar, Pete O'Heeron, CEO of FibroBiologics, and Jason Davis, CFO, will present an overview of the company’s strategy and current developments. The focus will be on the ongoing Phase 1/2 clinical trial for diabetic foot ulcers, which is evaluating the efficacy of CYWC628, the company’s lead program. The trial, expected to enroll up to 120 patients, will assess two doses of CYWC628 in combination with standard wound care against standard care alone.
FibroBiologics also plans to discuss its broader pipeline, which includes CYPS317, a program being developed for psoriasis. The company has submitted an Investigational New Drug (IND) application to the FDA, and a 12-week clinical study is anticipated following clearance. Additionally, the company is advancing CYMS101 for multiple sclerosis and CybroCell for degenerative disc disease, extending its platform across immune-mediated and regenerative applications.
The webinar will also highlight the company’s extensive intellectual property portfolio, which includes over 325 issued and pending patents. This robust patent portfolio provides significant support for the company’s multiple development programs and underscores its commitment to innovation in cell therapy and tissue regeneration.
RedChip Companies, an Inc. 5000 company, has been instrumental in promoting microcap and small-cap companies since its founding in 1992. Over the past 34 years, RedChip has evolved into a full-service investor relations and media firm, delivering measurable results for its clients. The company’s newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors, providing them with critical insights and updates on emerging companies.
The event will feature a live question and answer session, allowing participants to engage directly with the management team.
FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration, aiming to transform the treatment of chronic diseases and regenerative medicine. The upcoming webinar is expected to provide valuable insights into the company’s strategic direction and progress, making it a must-attend for investors and industry stakeholders.